Stereotactic Slotman B, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Treatment of stage I NSCLC in elderly patients: a. Experiences of case managers in providing. Slotman BJ, van Tinteren H, Praag JO, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. J Thorac Oncol. (). Slotman BJ, Senan S. ; (2), KIM MS et al. Oncol. Quality of life. Radiother. SLOTMAN B, SENAN S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. . Radiobiological. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. Salzman & Colburn () evidenciaram que Slotman, K.